---
title: Sample Pretreatment to Improve Drug Tolerance in ADA Assays
description: "Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL positive control."
image: https://www.crystalbiosolutions.com/hubfs/Improve-Drug-Tolerance-ADA-Assay.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Sep 16, 2025

# Sample Pretreatment Approaches to Improve Drug Tolerance in ADA Assays

Case study: adding an acid dissociation–affinity capture step raised ADA assay drug tolerance to at least 8 µg/mL of drug at 100 ng/mL positive control.

![Sample Pretreatment to Improve Drug Tolerance in ADA Assays](https://www.crystalbiosolutions.com/hubfs/Improve-Drug-Tolerance-ADA-Assay.png)\\

**Summary:** Adding an acid dissociation–affinity capture step before a standard bridging ADA assay raised drug tolerance from below 4 µg/mL to at least 8 µg/mL of drug at a positive control (PC) concentration of 100 ng/mL.

## Objective

Circulating drug can bind anti-drug antibodies (ADA) and mask them in a bridging assay. Acid dissociation followed by neutralization is a common countermeasure, but it is not always sufficient. In this study, for ADA against a prodrug, we added an acid dissociation–affinity capture step ahead of the standard procedure to improve drug tolerance.

## Challenge

The target was to tolerate at least 4 µg/mL of drug at a PC concentration of 100 ng/mL. The initial strategy (Strategy 1) treated samples with 300 mM acetic acid, then incubated them overnight with biotin- and ruthenium-labeled prodrug in 1 M Tris buffer (pH 9.5) before capture on an MSD streptavidin plate. It did not meet the target.

## Approach

In Strategy 2, ADA were captured on a prodrug-coated Nunc plate during acid pretreatment, eluted, and then carried through the standard bridging assay.

![Initial ADA pretreatment: acid dissociation, then capture on an MSD streptavidin plate with biotin- and Ru-labeled prodrug](https://www.crystalbiosolutions.com/hs-fs/hubfs/case-studies/figures/cbs-cs2-ada-acid-dissociation-initial-strategy.webp?width=762&height=450&name=cbs-cs2-ada-acid-dissociation-initial-strategy.webp)

**Figure 1.** Initial strategy: acid dissociation followed by bridging capture on an MSD streptavidin (SA) plate with biotin- and Ru-labeled prodrug. Drug tolerance did not meet the target.

![Improved ADA pretreatment: affinity capture on a prodrug-coated Nunc plate, second acid dissociation, then detection on an MSD SA plate](https://www.crystalbiosolutions.com/hs-fs/hubfs/case-studies/figures/cbs-cs2-ada-affinity-capture-pretreatment-strategy.webp?width=831&height=753&name=cbs-cs2-ada-affinity-capture-pretreatment-strategy.webp)

**Figure 2.** Improved strategy: first acid dissociation with affinity capture of ADA on a prodrug-coated Nunc plate (day 1), then a second acid dissociation and bridging detection on an MSD SA plate (day 2).

## Results

| Sample (PC – drug) | Strategy 1 signal (RLU) | Strategy 1 S/N | Strategy 2 signal (RLU) | Strategy 2 S/N |
| --- | --- | --- | --- | --- |
| 100 ng/mL PC – 4 µg/mL drug | 69 | 1.10 | 90 | 1.45 |
| 100 ng/mL PC – 8 µg/mL drug | 70 | 1.12 | 85 | 1.37 |

With Strategy 1, samples containing drug fell below the SCP of 1.2 and would be reported negative. With Strategy 2, both samples remained above the SCP, so the assay tolerated at least 8 µg/mL of drug at 100 ng/mL PC.

## Conclusions

- Combining acid dissociation with an ADA capture step can substantially improve drug tolerance.
- Other ADA enrichment approaches, such as capture on streptavidin magnetic beads or PEG precipitation, can serve the same purpose.

Related services: [ADA and NAb immunogenicity assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk).

## Download the case study

Fill in the short form below and we will email you the PDF (1 page, 883 KB).

To discuss a similar study, email [cbs\_bd@crystalpharmatech.com](mailto:cbs_bd@crystalpharmatech.com) or call +1 925-558-5040.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Crystal Bio Solutions Scientific Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/crystal-bio-solutions-scientific-team"
  },
  "dateModified" : "2026-11-21T21:20:20.228Z",
  "datePublished" : "2025-09-16T16:36:02.000Z",
  "headline" : "Sample Pretreatment to Improve Drug Tolerance in ADA Assays",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/Improve-Drug-Tolerance-ADA-Assay.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/pretreatment-approaches-to-improve-drug-tolerance-in-ada-assay",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```